Objective: To clear SGLT-2 inhibitors' effect on heart failure's cardiovascular prognosis and
cardiac function indexes, and to appraise SGLT-2 inhibitors' effects on different heart failure …

Purpose Numerous clinical studies have explored sodium–glucose cotransporter 2 inhibitor
(SGLT2i) in patients with chronic heart failure (CHF), with or without type 2 diabetes mellitus …

Background Heart failure (HF) prognosis without therapy is poor, however introduction of a
range of drugs has improved it. We aimed to perform a systematic review on the effects and …

Background: The purpose of this systematic review and meta-analysis was to determine the
effects of SGLT2 inhibitors on major heart failure outcomes (such as HHF and CVD) in …

Introduction: This meta-analysis aimed to investigate the effect of SGLT2 inhibitors on the
prognosis of patients with heart failure (HF) or at risk of HF across different body mass index …

Aims: The aim of this study was to synthesize the evidence on the effects of SGLT2i on
multiple outcomes in the treatment of heart failure and to analyze the effects of different …

Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been recommended
in the practice guidelines for the treatment of patients with heart failure with reduced ejection …

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in
improving cardiovascular outcome in patients with heart failure (HF) and diabetes mellitus …

Abstract Funding Acknowledgements Type of funding sources: None. Aims We aimed to
carry out a meta-analysis on the effectiveness of sodium-glucose co transporter 2 (SGLT2) …

This article comprehensively analyzes the existing treatment methods for chronic heart
failure (CHF), and focuses on exploring the research progress in new therapeutic drugs in …